Regeneron Pharmaceuticals Inc Stock Forecast for 2023 - 2025 - 2030

Updated on 11/29/2023

Stock Rating
2
Price Target
$914.00
Consensus
Outperform
Upside
14.09%
Analysts
9
Stock Rating
2
Upside
14.09%
Analysts
9
Price Target
$914.00

Regeneron Pharmaceuticals Inc Stock Forecast and Price Target

The average target price for Regeneron Pharmaceuticals Inc's stock set by nine renowned analysts in recent months is $914.00, representing a potential upside of approximately 14.09% from its last closing price if met by 2024. This estimation is based on a high estimate of $1066.00 and a low estimate of $680.00. If you want to invest in REGN stock, you might also want to take a look at how its competitors are doing.

$914.00

14.09% Upside

Outperform
Outperform

Regeneron Pharmaceuticals Inc Fair Value Forecast for 2023 - 2025 - 2030

In the last three years, Regeneron Pharmaceuticals Inc's Price has seen an increase, rising from $376.22 to $685.95. This represents a growth of 82.33%. Analysts predict that Regeneron Pharmaceuticals Inc's Fair Value will increase in the upcoming year, reaching $700.43. This would represent an increase of 2.11%. Professionals believe that By 2030, Regeneron Pharmaceuticals Inc's Fair Value will fall to $614.12– a 10.47% decrease from its current value.

2023 Fair Value Forecast
$700.43
2024 Fair Value Forecast
$727.27
2025 Fair Value Forecast
$725.75
2026 Fair Value Forecast
$709.58
2027 Fair Value Forecast
$673.90
2028 Fair Value Forecast
$636.99
2029 Fair Value Forecast
$623.88
2030 Fair Value Forecast
$614.12
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
LLY Stock Forecast Eli Lilly & Co Outperform 16
$591.60 Buy/Sell $594.01 9.87%
JNJ Stock Forecast Johnson & Johnson Outperform 10
$151.63 Buy/Sell $176.14 13.43%
MRK Stock Forecast Merck Outperform 5
$100.18 Buy/Sell $123.75 24.78%
PFE Stock Forecast Pfizer Inc Outperform 3
$29.69 Buy/Sell $40.55 26.31%
BMY Stock Forecast Bristol-Myers Squibb Co Outperform 2
$48.92 Buy/Sell $64.26 25.72%

Regeneron Pharmaceuticals Inc Revenue Forecast for 2023 - 2025 - 2030

In the last three years, Regeneron Pharmaceuticals Inc's Revenue has seen an increase, rising from $6.56B to $12.17B. This represents a growth of 85.63%. Analysts predict that Regeneron Pharmaceuticals Inc's Revenue will increase in the upcoming year, reaching $12.43B. This would represent an increase of 2.08%. Professionals believe that By 2030, Regeneron Pharmaceuticals Inc's Revenue will fall to $11.25B– a 7.55% decrease from its current value.

2023 Rev Forecast
$12.43B
2024 Rev Forecast
$12.85B
2025 Rev Forecast
$12.88B
2026 Rev Forecast
$12.82B
2027 Rev Forecast
$11.97B
2028 Rev Forecast
$11.70B
2029 Rev Forecast
$11.62B
2030 Rev Forecast
$11.25B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
VRTX Stock Forecast Vertex Pharmaceuticals Inc Outperform 15
$347.04 Buy/Sell $395.90 12.38%
ZTS Stock Forecast Zoetis Inc Outperform 18
$176.97 Buy/Sell $217.57 18.66%
ALNY Stock Forecast Alnylam Pharmaceuticals Inc Outperform 7
$161.36 Buy/Sell $245.24 42.54%

Regeneron Pharmaceuticals Inc Dividend per Share Forecast for 2023 - 2025 - 2030

2023 DPS Forecast
$0.00
2024 DPS Forecast
$0.00
2025 DPS Forecast
$0.00
2026 DPS Forecast
$0.00
2027 DPS Forecast
$0.00
2028 DPS Forecast
$0.00
2029 DPS Forecast
$0.00
2030 DPS Forecast
$0.00
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BAX Stock Forecast Baxter International Inc Outperform 17
$36.34 Buy/Sell $45.50 22.45%
VTRS Stock Forecast Viatris Inc Hold 8
$9.14 Buy/Sell $11.74 25.82%
UTHR Stock Forecast United Therapeutics Corp Outperform 12
$230.39 Buy/Sell $278.82 30.21%

Regeneron Pharmaceuticals Inc Free Cash Flow Forecast for 2023 - 2025 - 2030

Regeneron Pharmaceuticals Inc's Free Cash Flow has grown in the last three years, jumping from $2.00B to $4.46B – an increase of 123.11%. In the next year, analysts predict that Free Cash Flow will reach $5.57B – an increase of 24.73%. For the next eight years, the forecast is for Free Cash Flow to grow by 15.75%.

2023 FCF Forecast
$5.57B
2024 FCF Forecast
$5.63B
2025 FCF Forecast
$5.70B
2026 FCF Forecast
$5.50B
2027 FCF Forecast
$5.38B
2028 FCF Forecast
$5.38B
2029 FCF Forecast
$5.26B
2030 FCF Forecast
$5.17B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
IONS Stock Forecast Ionis Pharmaceuticals Inc Outperform 9
$48.34 Buy/Sell $51.20 24.12%
CTLT Stock Forecast Catalent Outperform 15
$39.46 Buy/Sell $49.29 21.64%
BCPC Stock Forecast Balchem Outperform 18
$122.71 Buy/Sell $145.00 22.24%

Regeneron Pharmaceuticals Inc Net Income Forecast for 2023 - 2025 - 2030

In the last three years, Net Income for Regeneron Pharmaceuticals Inc has grown by 105.05%, going from $2.12B to $4.34B. In the coming year, analysts are expecting an increase in Net Income, predicting it will reach $5.24B – an increase of 20.85%. Over the next eight years, experts anticipate that Net Income growth for Regeneron Pharmaceuticals Inc will be 7.92%.

2023 NI Forecast
$5.24B
2024 NI Forecast
$5.45B
2025 NI Forecast
$5.43B
2026 NI Forecast
$5.36B
2027 NI Forecast
$5.06B
2028 NI Forecast
$4.82B
2029 NI Forecast
$4.74B
2030 NI Forecast
$4.68B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
MDGL Stock Forecast Madrigal Pharmaceuticals Outperform 4
$190.94 Buy/Sell $170.08 73.09%
NEOG Stock Forecast Neogen Outperform 16
$16.60 Buy/Sell $37.00 34.04%
CYTK Stock Forecast Cytokinetics Inc Outperform 10
$31.22 Buy/Sell $61.75 92.18%

Regeneron Pharmaceuticals Inc EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, Regeneron Pharmaceuticals Inc's EBITDA has increased by 117.30%, going from $2.46B to $5.34B. In the next year, analysts are expecting an increase in EBITDA, predicting it will reach $6.59B – an increase of 23.48%. The Regeneron Pharmaceuticals Inc forecast is for EBITDA to reach $5.97B or grow by 11.80%.

2023 EBITDA Forecast
$6.59B
2024 EBITDA Forecast
$7.12B
2025 EBITDA Forecast
$6.93B
2026 EBITDA Forecast
$6.98B
2027 EBITDA Forecast
$5.47B
2028 EBITDA Forecast
$5.62B
2029 EBITDA Forecast
$5.79B
2030 EBITDA Forecast
$5.97B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
AMPH Stock Forecast Amphastar Pharmaceuticals Outperform 14
$54.41 Buy/Sell $69.00 21.30%
CORT Stock Forecast Corcept Therapeutics Outperform 16
$25.45 Buy/Sell $0.00 41.45%
INDV Stock Forecast Indivior PLC Buy 14
£12.38 Buy/Sell £3.79 134.25%

Regeneron Pharmaceuticals Inc EBIT Forecast for 2023 - 2025 - 2030

In the last three years, Regeneron Pharmaceuticals Inc's EBIT has grown, increasing from $2.25B to $4.99B – an increase of 122.45%. For next year, the 5 analysts predict EBIT of $5.25B, which would mean an increase of 5.13%. In 2030, the professionals' prediction is that REGN's EBIT will decrease by 11.37%, reaching $4.43B.

2023 EBIT Forecast
$5.25B
2024 EBIT Forecast
$5.27B
2025 EBIT Forecast
$5.62B
2026 EBIT Forecast
$6.90B
2027 EBIT Forecast
$6.84B
2028 EBIT Forecast
$4.67B
2029 EBIT Forecast
$4.27B
2030 EBIT Forecast
$4.43B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
TGTX Stock Forecast TG Therapeutics Outperform 9
$12.63 Buy/Sell $26.83 90.02%
CPRX Stock Forecast Catalyst Pharmaceuticals Outperform 16
$14.21 Buy/Sell $23.30 75.93%
IRWD Stock Forecast Ironwood Pharmaceuticals Outperform 14
$9.68 Buy/Sell $17.40 106.61%

Regeneron Pharmaceuticals Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last three years, Regeneron Pharmaceuticals Inc's EPS has seen an increase, rising from $24.67 to $44.98. This represents a growth of 82.33%. Analysts predict that Regeneron Pharmaceuticals Inc's EPS will increase in the upcoming year, reaching $45.93. This would represent an increase of 2.11%. Professionals believe that By 2030, Regeneron Pharmaceuticals Inc's EPS will fall to $40.27– a 10.47% decrease from its current value.

2023 EPS Forecast
$45.93
2024 EPS Forecast
$47.69
2025 EPS Forecast
$47.59
2026 EPS Forecast
$46.53
2027 EPS Forecast
$44.19
2028 EPS Forecast
$41.77
2029 EPS Forecast
$40.91
2030 EPS Forecast
$40.27
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
SUPN Stock Forecast Supernus Pharmaceuticals Outperform 16
$26.97 Buy/Sell $41.00 53.87%
ARPO Stock Forecast Aerpio Pharmaceuticals - 6
$30.30 Buy/Sell $0.00 -100.00%
PCRX Stock Forecast Pacira BioSciences Outperform 16
$27.50 Buy/Sell $49.11 81.82%